Chinese General Practice ›› 2023, Vol. 26 ›› Issue (05): 550-556.DOI: 10.12114/j.issn.1007-9572.2022.0583
Special Issue: 呼吸疾病文章合集; 新型冠状病毒肺炎最新文章合集; COVID-19疫情防控研究
• Original Research • Previous Articles Next Articles
Received:
2022-06-11
Revised:
2022-09-22
Published:
2023-02-15
Online:
2022-10-08
Contact:
WANG Fengyan
通讯作者:
王凤燕
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0583
组别 | 例数 | 男性〔n(%)〕 | 年龄( | mMRC〔n(%)〕 | CAT〔M(P25,P75),分〕 | CAT〔n(%)〕 | FEV1%pred〔M(P25,P75),%〕 | |||
---|---|---|---|---|---|---|---|---|---|---|
0~1分 | 2~4分 | <10分 | ≥10分 | |||||||
Ⅳ组 | 159 | 153(96.2) | 66.8±8.0 | 83(52.2) | 76(47.8) | 10(6,13) | 77(48.4) | 82(51.6) | 45.1(33.3,63.2) | |
Ⅰ组 | 162 | 153(94.4) | 66.6±7.9 | 84(51.8) | 78(48.2) | 11(7,15) | 66(40.7) | 96(59.3) | 44.2(30.5,59.15) | |
检验统计量值 | 0.572a | 0.255b | 0.004a | -1.961 | 1.919a | -0.981 | ||||
P值 | 0.449 | 0.822 | 0.95 | 0.050 | 0.166 | 0.327 | ||||
Ⅳ组 | 159 | 153(96.2) | 66.8±8.0 | 83(52.2) | 76(47.8) | 10(6,13) | 77(48.4) | 82(51.6) | 45.1(33.3,63.2) | |
Ⅱ组 | 157 | 146(93.0) | 67.7±7.6 | 97(61.8) | 60(38.2) | 10(6.5,15) | 69(44.0) | 88(56.0) | 52.1(36.2,70.1) | |
检验统计量值 | 1.622a | -1.037b | 2.959a | -1.346 | 0.637a | -1.911 | ||||
P值 | 0.203 | 0.300 | 0.085 | 0.178 | 0.425 | 0.056 | ||||
Ⅳ组 | 159 | 153(96.2) | 66.8±8.0 | 83(52.2) | 76(47.8) | 10(6,13) | 77(48.4) | 82(51.6) | 45.1(33.3,63.2) | |
Ⅲ组 | 167 | 157(94.0) | 66.5±7.8 | 90(53.9) | 77(46.1) | 10(6,14) | 78(46.7) | 89(53.3) | 42.6(32.5,58.0) | |
检验统计量值 | 0.856a | 0.302b | 0.094a | -0.541 | 0.097a | -1.127 | ||||
P值 | 0.355 | 0.763 | 0.760 | 0.589 | 0.756 | 0.260 | ||||
组别 | FEV1%pred分级〔n(%)〕 | 吸烟史〔M(P25,P75),包/年〕 | 吸入用药史〔n(%)〕 | |||||||
<30% | [30%,50%) | [50%,80%) | ≥80% | ICS+LABA+LAMA | ICS+LABA | LABA+LAMA | LAMA | 其他 | ||
Ⅳ组 | 27(17.0) | 63(39.6) | 52(32.7) | 17(10.7) | 35(15,50) | 66(41.5) | 53(33.3) | 1(0.6) | 21(13.2) | 18(11.3) |
Ⅰ组 | 38(23.5) | 59(36.4) | 51(31.5) | 14(8.6) | 30(10,45) | 66(40.7) | 57(35.2) | 8(4.9) | 15(9.3) | 16(9.9) |
检验统计量值 | 2.084a | 0.349a | 0.055a | 0.386a | -1.136 | 0.020a | 0.122a | — | 1.256a | 0.177a |
P值 | 0.149 | 0.554 | 0.814 | 0.534 | 0.256 | 0.889 | 0.727 | 0.037 | 0.262 | 0.674 |
Ⅳ组 | 27(17.0) | 63(39.6) | 52(32.7) | 17(10.7) | 35(15,50) | 66(41.5) | 53(33.3) | 1(0.6) | 21(13.2) | 18(11.3) |
Ⅱ组 | 22(14.0) | 52(33.1) | 65(41.4) | 18(11.5) | 30(8,40) | 47(29.9) | 67(42.7) | 2(1.3) | 23(14.6) | 18(11.5) |
检验统计量值 | 0.531a | 1.443a | 2.563a | 0.048a | -2.210 | 4.606a | 2.927a | — | 0.137a | 0.002a |
P值 | 0.466 | 0.230 | 0.109 | 0.827 | 0.027 | 0.032 | 0.087 | 0.621 | 0.711 | 0.968 |
Ⅳ组 | 27(17.0) | 63(39.6) | 52(32.7) | 17(10.7) | 35(15,50) | 66(41.5) | 53(33.3) | 1(0.6) | 21(13.2) | 18(11.3) |
Ⅲ组 | 35(21.0) | 69(41.3) | 50(29.9) | 13(7.8) | 35(15,50) | 74(44.3) | 46(27.5) | 2(1.2) | 30(18.0) | 15(9.0) |
检验统计量值 | 0.836a | 0.097a | 0.289a | 0.824a | -0.164 | 0.261a | 1.291a | — | 1.396a | 0.490a |
P值 | 0.360 | 0.755 | 0.591 | 0.364 | 0.869 | 0.609 | 0.256 | 1.000 | 0.237 | 0.484 |
Table 1 Comparison of basic data of four groups of patients
组别 | 例数 | 男性〔n(%)〕 | 年龄( | mMRC〔n(%)〕 | CAT〔M(P25,P75),分〕 | CAT〔n(%)〕 | FEV1%pred〔M(P25,P75),%〕 | |||
---|---|---|---|---|---|---|---|---|---|---|
0~1分 | 2~4分 | <10分 | ≥10分 | |||||||
Ⅳ组 | 159 | 153(96.2) | 66.8±8.0 | 83(52.2) | 76(47.8) | 10(6,13) | 77(48.4) | 82(51.6) | 45.1(33.3,63.2) | |
Ⅰ组 | 162 | 153(94.4) | 66.6±7.9 | 84(51.8) | 78(48.2) | 11(7,15) | 66(40.7) | 96(59.3) | 44.2(30.5,59.15) | |
检验统计量值 | 0.572a | 0.255b | 0.004a | -1.961 | 1.919a | -0.981 | ||||
P值 | 0.449 | 0.822 | 0.95 | 0.050 | 0.166 | 0.327 | ||||
Ⅳ组 | 159 | 153(96.2) | 66.8±8.0 | 83(52.2) | 76(47.8) | 10(6,13) | 77(48.4) | 82(51.6) | 45.1(33.3,63.2) | |
Ⅱ组 | 157 | 146(93.0) | 67.7±7.6 | 97(61.8) | 60(38.2) | 10(6.5,15) | 69(44.0) | 88(56.0) | 52.1(36.2,70.1) | |
检验统计量值 | 1.622a | -1.037b | 2.959a | -1.346 | 0.637a | -1.911 | ||||
P值 | 0.203 | 0.300 | 0.085 | 0.178 | 0.425 | 0.056 | ||||
Ⅳ组 | 159 | 153(96.2) | 66.8±8.0 | 83(52.2) | 76(47.8) | 10(6,13) | 77(48.4) | 82(51.6) | 45.1(33.3,63.2) | |
Ⅲ组 | 167 | 157(94.0) | 66.5±7.8 | 90(53.9) | 77(46.1) | 10(6,14) | 78(46.7) | 89(53.3) | 42.6(32.5,58.0) | |
检验统计量值 | 0.856a | 0.302b | 0.094a | -0.541 | 0.097a | -1.127 | ||||
P值 | 0.355 | 0.763 | 0.760 | 0.589 | 0.756 | 0.260 | ||||
组别 | FEV1%pred分级〔n(%)〕 | 吸烟史〔M(P25,P75),包/年〕 | 吸入用药史〔n(%)〕 | |||||||
<30% | [30%,50%) | [50%,80%) | ≥80% | ICS+LABA+LAMA | ICS+LABA | LABA+LAMA | LAMA | 其他 | ||
Ⅳ组 | 27(17.0) | 63(39.6) | 52(32.7) | 17(10.7) | 35(15,50) | 66(41.5) | 53(33.3) | 1(0.6) | 21(13.2) | 18(11.3) |
Ⅰ组 | 38(23.5) | 59(36.4) | 51(31.5) | 14(8.6) | 30(10,45) | 66(40.7) | 57(35.2) | 8(4.9) | 15(9.3) | 16(9.9) |
检验统计量值 | 2.084a | 0.349a | 0.055a | 0.386a | -1.136 | 0.020a | 0.122a | — | 1.256a | 0.177a |
P值 | 0.149 | 0.554 | 0.814 | 0.534 | 0.256 | 0.889 | 0.727 | 0.037 | 0.262 | 0.674 |
Ⅳ组 | 27(17.0) | 63(39.6) | 52(32.7) | 17(10.7) | 35(15,50) | 66(41.5) | 53(33.3) | 1(0.6) | 21(13.2) | 18(11.3) |
Ⅱ组 | 22(14.0) | 52(33.1) | 65(41.4) | 18(11.5) | 30(8,40) | 47(29.9) | 67(42.7) | 2(1.3) | 23(14.6) | 18(11.5) |
检验统计量值 | 0.531a | 1.443a | 2.563a | 0.048a | -2.210 | 4.606a | 2.927a | — | 0.137a | 0.002a |
P值 | 0.466 | 0.230 | 0.109 | 0.827 | 0.027 | 0.032 | 0.087 | 0.621 | 0.711 | 0.968 |
Ⅳ组 | 27(17.0) | 63(39.6) | 52(32.7) | 17(10.7) | 35(15,50) | 66(41.5) | 53(33.3) | 1(0.6) | 21(13.2) | 18(11.3) |
Ⅲ组 | 35(21.0) | 69(41.3) | 50(29.9) | 13(7.8) | 35(15,50) | 74(44.3) | 46(27.5) | 2(1.2) | 30(18.0) | 15(9.0) |
检验统计量值 | 0.836a | 0.097a | 0.289a | 0.824a | -0.164 | 0.261a | 1.291a | — | 1.396a | 0.490a |
P值 | 0.360 | 0.755 | 0.591 | 0.364 | 0.869 | 0.609 | 0.256 | 1.000 | 0.237 | 0.484 |
组别 | 例数 | 10月至次年1月 | 2—5月 | Z值 | P值 |
---|---|---|---|---|---|
Ⅰ组 | 162 | 43(26.5) | 68(42.0) | -2.495 | 0.013 |
Ⅱ组 | 157 | 34(21.7) | 54(34.4) | -2.406 | 0.016 |
Ⅲ组 | 167 | 45(27.0) | 61(36.5) | -1.621 | 0.105 |
Ⅳ组 | 159 | 30(18.9) | 9(5.7) | -3.362 | 0.001 |
Table 2 Comparison of the frequency of acute exacerbation of COPD among four groups of patients in periods from October to January next year and from February to May
组别 | 例数 | 10月至次年1月 | 2—5月 | Z值 | P值 |
---|---|---|---|---|---|
Ⅰ组 | 162 | 43(26.5) | 68(42.0) | -2.495 | 0.013 |
Ⅱ组 | 157 | 34(21.7) | 54(34.4) | -2.406 | 0.016 |
Ⅲ组 | 167 | 45(27.0) | 61(36.5) | -1.621 | 0.105 |
Ⅳ组 | 159 | 30(18.9) | 9(5.7) | -3.362 | 0.001 |
组别 | 例数 | 10月 | 11月 | 12月 | 次年1月 | 次年2月 | 次年3月 | 次年4月 | 次年5月 | 10月至次年1月 | 次年2—5月 |
---|---|---|---|---|---|---|---|---|---|---|---|
Ⅳ组 | 159 | 11(6.9) | 7(4.4) | 7(4.4) | 5(3.1) | 1(0.6) | 3(1.9) | 0 | 5(3.1) | 30(18.9) | 9(5.7) |
Ⅰ组 | 162 | 6(3.7) | 7(4.3) | 12(7.4) | 18(11.1) | 14(8.6) | 16(9.9) | 18(11.1) | 20(12.4) | 43(26.5) | 68(42.0) |
χ2值 | 1.65 | 0.001 | 1.301 | 7.656 | 11.566 | 9.199 | 18.716 | 9.459 | 2.690 | 58.037 | |
P值 | 0.199 | 0.971 | 0.254 | 0.006 | 0.001 | 0.002 | <0.001 | 0.002 | 0.101 | <0.001 | |
Ⅳ组 | 159 | 11(6.9) | 7(4.4) | 7(4.4) | 5(3.1) | 1(0.6) | 3(1.9) | 0 | 5(3.1) | 30(18.9) | 9(5.7) |
Ⅱ组 | 157 | 6(3.8) | 5(3.2) | 11(7.0) | 12(7.6) | 13(8.3) | 18(11.5) | 10(6.4) | 13(8.3) | 34(21.0) | 54(34.4) |
χ2值 | 1.488 | 0.321 | 0.997 | 3.141 | 0.923 | 11.682 | 10.458 | 3.879 | 0.380 | 40.863 | |
P值 | 0.223 | 0.571 | 0.318 | 0.076 | 0.001 | 0.001 | 0.001 | 0.049 | 0.537 | <0.001 | |
Ⅳ组 | 159 | 11(6.9) | 7(4.4) | 7(4.4) | 5(3.1) | 1(0.6) | 3(1.9) | 0 | 5(3.1) | 30(18.9) | 9(5.7) |
Ⅲ组 | 167 | 7(4.2) | 10(6.0) | 6(3.6) | 22(13.2) | 12(7.2) | 21(12.6) | 16(9.6) | 12(7.2) | 45(27.0) | 61(36.5) |
χ2值 | 1.161 | 9.414 | 0.139 | 10.785 | 9.146 | 13.643 | 14.970 | 2.691 | 3.001 | 46.022 | |
P值 | 0.281 | 0.520 | 0.709 | 0.001 | 0.002 | <0.001 | <0.001 | 0.101 | 0.083 | <0.001 |
Table 3 Comparison of frequency of acute exacerbation of COPD between group 4 and the other three groups during the same period
组别 | 例数 | 10月 | 11月 | 12月 | 次年1月 | 次年2月 | 次年3月 | 次年4月 | 次年5月 | 10月至次年1月 | 次年2—5月 |
---|---|---|---|---|---|---|---|---|---|---|---|
Ⅳ组 | 159 | 11(6.9) | 7(4.4) | 7(4.4) | 5(3.1) | 1(0.6) | 3(1.9) | 0 | 5(3.1) | 30(18.9) | 9(5.7) |
Ⅰ组 | 162 | 6(3.7) | 7(4.3) | 12(7.4) | 18(11.1) | 14(8.6) | 16(9.9) | 18(11.1) | 20(12.4) | 43(26.5) | 68(42.0) |
χ2值 | 1.65 | 0.001 | 1.301 | 7.656 | 11.566 | 9.199 | 18.716 | 9.459 | 2.690 | 58.037 | |
P值 | 0.199 | 0.971 | 0.254 | 0.006 | 0.001 | 0.002 | <0.001 | 0.002 | 0.101 | <0.001 | |
Ⅳ组 | 159 | 11(6.9) | 7(4.4) | 7(4.4) | 5(3.1) | 1(0.6) | 3(1.9) | 0 | 5(3.1) | 30(18.9) | 9(5.7) |
Ⅱ组 | 157 | 6(3.8) | 5(3.2) | 11(7.0) | 12(7.6) | 13(8.3) | 18(11.5) | 10(6.4) | 13(8.3) | 34(21.0) | 54(34.4) |
χ2值 | 1.488 | 0.321 | 0.997 | 3.141 | 0.923 | 11.682 | 10.458 | 3.879 | 0.380 | 40.863 | |
P值 | 0.223 | 0.571 | 0.318 | 0.076 | 0.001 | 0.001 | 0.001 | 0.049 | 0.537 | <0.001 | |
Ⅳ组 | 159 | 11(6.9) | 7(4.4) | 7(4.4) | 5(3.1) | 1(0.6) | 3(1.9) | 0 | 5(3.1) | 30(18.9) | 9(5.7) |
Ⅲ组 | 167 | 7(4.2) | 10(6.0) | 6(3.6) | 22(13.2) | 12(7.2) | 21(12.6) | 16(9.6) | 12(7.2) | 45(27.0) | 61(36.5) |
χ2值 | 1.161 | 9.414 | 0.139 | 10.785 | 9.146 | 13.643 | 14.970 | 2.691 | 3.001 | 46.022 | |
P值 | 0.281 | 0.520 | 0.709 | 0.001 | 0.002 | <0.001 | <0.001 | 0.101 | 0.083 | <0.001 |
Figure 3 Temporal trends of the frequency of acute exacerbation of COPD without medical attention during eight months(from October to May next year)in four groups of patients
组别 | 例数 | 10月 | 11月 | 12月 | 次年1月 | 次年2月 | 次年3月 | 次年4月 | 次年5月 |
---|---|---|---|---|---|---|---|---|---|
Ⅳ组 | 159 | 1(0.6) | 3(1.9) | 2(1.3) | 1(0.6) | 0 | 2(1.3) | 0 | 0 |
Ⅰ组 | 162 | 1(0.6) | 3(1.8) | 1(0.6) | 2(1.2) | 1(0.6) | 3(1.8) | 4(2.5) | 3(1.8) |
χ2值 | — | — | — | — | — | — | — | — | |
P值 | 1.000 | 1.000 | 0.620 | 1.000 | 1.000 | 1.000 | 0.123 | 0.248 | |
Ⅳ组 | 159 | 1(0.6) | 3(1.9) | 2(1.3) | 1(0.6) | 0 | 2(1.3) | 0 | 0 |
Ⅱ组 | 157 | 1(0.6) | 0 | 2(1.3) | 4(2.6) | 3(1.9) | 0 | 3(1.9) | 5(3.2) |
χ2值 | — | — | — | — | — | — | — | — | |
P值 | 1.000 | 0.248 | 1.000 | 0.213 | 0.121 | 0.498 | 0.121 | 0.029 | |
Ⅳ组 | 159 | 1(0.6) | 3(1.9) | 2(1.3) | 1(0.6) | 0 | 2(1.3) | 0 | 0 |
Ⅲ组 | 167 | 1(0.6) | 1(0.6) | 1(0.6) | 0 | 3(1.8) | 2(1.2) | 4(2.4) | 1(0.6) |
χ2值 | — | — | — | — | — | — | — | — | |
P值 | 1.000 | 0.361 | 0.615 | 0.488 | 0.248 | 1.000 | 0.123 | 1.000 |
Table 4 Comparison on the frequency of acute exacerbations of COPD without medical attention during eight months(from October to May next year) among four groups
组别 | 例数 | 10月 | 11月 | 12月 | 次年1月 | 次年2月 | 次年3月 | 次年4月 | 次年5月 |
---|---|---|---|---|---|---|---|---|---|
Ⅳ组 | 159 | 1(0.6) | 3(1.9) | 2(1.3) | 1(0.6) | 0 | 2(1.3) | 0 | 0 |
Ⅰ组 | 162 | 1(0.6) | 3(1.8) | 1(0.6) | 2(1.2) | 1(0.6) | 3(1.8) | 4(2.5) | 3(1.8) |
χ2值 | — | — | — | — | — | — | — | — | |
P值 | 1.000 | 1.000 | 0.620 | 1.000 | 1.000 | 1.000 | 0.123 | 0.248 | |
Ⅳ组 | 159 | 1(0.6) | 3(1.9) | 2(1.3) | 1(0.6) | 0 | 2(1.3) | 0 | 0 |
Ⅱ组 | 157 | 1(0.6) | 0 | 2(1.3) | 4(2.6) | 3(1.9) | 0 | 3(1.9) | 5(3.2) |
χ2值 | — | — | — | — | — | — | — | — | |
P值 | 1.000 | 0.248 | 1.000 | 0.213 | 0.121 | 0.498 | 0.121 | 0.029 | |
Ⅳ组 | 159 | 1(0.6) | 3(1.9) | 2(1.3) | 1(0.6) | 0 | 2(1.3) | 0 | 0 |
Ⅲ组 | 167 | 1(0.6) | 1(0.6) | 1(0.6) | 0 | 3(1.8) | 2(1.2) | 4(2.4) | 1(0.6) |
χ2值 | — | — | — | — | — | — | — | — | |
P值 | 1.000 | 0.361 | 0.615 | 0.488 | 0.248 | 1.000 | 0.123 | 1.000 |
组别 | 例数 | 10月 | 11月 | 12月 | 次年1月 | 次年2月 | 次年3月 | 次年4月 | 次年5月 |
---|---|---|---|---|---|---|---|---|---|
Ⅳ组 | 159 | 10(6.3) | 4(2.5) | 5(3.1) | 4(2.5) | 1(0.6) | 1(0.6) | 0 | 5(3.1) |
Ⅰ组 | 162 | 5(3.1) | 4(2.5) | 11(6.8) | 16(9.9) | 13(8.0) | 13(8.0) | 14(8.6) | 16(9.9) |
χ2值 | 1.848 | — | 2.252 | 7.442 | 10.522 | 10.522 | 14.367 | 5.948 | |
P值 | 0.174 | 1.000 | 0.133 | 0.006 | 0.001 | 0.001 | <0.001 | 0.015 | |
Ⅳ组 | 159 | 10(6.3) | 4(2.5) | 5(3.1) | 4(2.5) | 1(0.6) | 1(0.6) | 0 | 5(3.1) |
Ⅱ组 | 157 | 5(3.2) | 4(2.6) | 9(5.7) | 8(5.1) | 10(6.4) | 18(11.5) | 7(4.5) | 8(5.1) |
χ2值 | 1.684 | — | 1.249 | 1.439 | 7.748 | 16.414 | 7.250 | 0.762 | |
P值 | 0.194 | 1.000 | 0.264 | 0.230 | 0.005 | <0.001 | 0.021 | 0.383 | |
Ⅳ组 | 159 | 10(6.3) | 4(2.5) | 5(3.1) | 4(2.5) | 1(0.6) | 1(0.6) | 0 | 5(3.1) |
Ⅲ组 | 167 | 6(3.6) | 9(5.4) | 5(3.0) | 22(13.2) | 9(5.4) | 19(11.4) | 12(7.2) | 11(6.6) |
χ2值 | 1.269 | 1.757 | — | 12.606 | — | 16.340 | 11.862 | 2.968 | |
P值 | 0.260 | 0.185 | 1.000 | <0.001 | 0.020 | <0.001 | 0.001 | 0.015 |
Table 5 Comparison of the frequency of visits for acute exacerbation of COPD during eight months(from October to May next year) among four groups of patients
组别 | 例数 | 10月 | 11月 | 12月 | 次年1月 | 次年2月 | 次年3月 | 次年4月 | 次年5月 |
---|---|---|---|---|---|---|---|---|---|
Ⅳ组 | 159 | 10(6.3) | 4(2.5) | 5(3.1) | 4(2.5) | 1(0.6) | 1(0.6) | 0 | 5(3.1) |
Ⅰ组 | 162 | 5(3.1) | 4(2.5) | 11(6.8) | 16(9.9) | 13(8.0) | 13(8.0) | 14(8.6) | 16(9.9) |
χ2值 | 1.848 | — | 2.252 | 7.442 | 10.522 | 10.522 | 14.367 | 5.948 | |
P值 | 0.174 | 1.000 | 0.133 | 0.006 | 0.001 | 0.001 | <0.001 | 0.015 | |
Ⅳ组 | 159 | 10(6.3) | 4(2.5) | 5(3.1) | 4(2.5) | 1(0.6) | 1(0.6) | 0 | 5(3.1) |
Ⅱ组 | 157 | 5(3.2) | 4(2.6) | 9(5.7) | 8(5.1) | 10(6.4) | 18(11.5) | 7(4.5) | 8(5.1) |
χ2值 | 1.684 | — | 1.249 | 1.439 | 7.748 | 16.414 | 7.250 | 0.762 | |
P值 | 0.194 | 1.000 | 0.264 | 0.230 | 0.005 | <0.001 | 0.021 | 0.383 | |
Ⅳ组 | 159 | 10(6.3) | 4(2.5) | 5(3.1) | 4(2.5) | 1(0.6) | 1(0.6) | 0 | 5(3.1) |
Ⅲ组 | 167 | 6(3.6) | 9(5.4) | 5(3.0) | 22(13.2) | 9(5.4) | 19(11.4) | 12(7.2) | 11(6.6) |
χ2值 | 1.269 | 1.757 | — | 12.606 | — | 16.340 | 11.862 | 2.968 | |
P值 | 0.260 | 0.185 | 1.000 | <0.001 | 0.020 | <0.001 | 0.001 | 0.015 |
Figure 4 Temporal trends of the frequency of visits for acute exacerbation of COPD during eight months(from October to May next year) in four groups of patients
[1] |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志,2021,44(3):170-205. DOI:10.3760/cma.j.cn112147-20210109-00031.
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease (2017-2020 REPORT)[EB/OL]. [2022-03-11].
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[1] | YANG Huajie, WANG Haoxiang, CHEN Yuncong, LIANG Xudong, WANG Jiaji, HUANG Xiang. Status and Influencing Factors of Mental Health of Community Medical Personnel during the Normalized Prevention and Control of COVID-19 [J]. Chinese General Practice, 2024, 27(07): 834-842. |
[2] | YANG Mukun, JIA Xiaoxiang, REN Zhenghong, GU Bei, BAI Wenpei. Menopause or Chronologic Aging? A Prospective Cohort Study on Risk Factors for Coronary Heart Disease in Middle-aged Women [J]. Chinese General Practice, 2024, 27(03): 280-285. |
[3] | ZHENG Jinping, XUE Wujun, JU Chunrong, MA Jun, ZENG Xiaofeng. Identification of COVID-19 Infection in Vulnerable Population and Its Prevention and Treatment Perspectives [J]. Chinese General Practice, 2024, 27(02): 132-137. |
[4] | ZHOU Jing, JIA Jianguo, LIN Yixin, WU Shuang, DAI Shilong, WANG Mingjun, ZHANG Qingsong. Association of Different Metabolic Obesity Phenotypes with Breast Cancer Risk in Women: a Prospective Cohort Study [J]. Chinese General Practice, 2024, 27(02): 150-155. |
[5] | WANG Jing, WANG Hui, SONG Shiqun, JI Guanghe, GUO Yakun, YAO Danning, ZHAO Shuhan, LI Duoduo, XIA Ruyu, ZHANG Lishan. Literature Characteristics and Outcome Measures of Randomized Controlled Trials of Oral Traditional Chinese Medicine in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2024, 27(02): 226-232. |
[6] | YANG Lichao, ZENG Huatang, HU Mengzhi, WU Liqun, TIAN Qiannan, WEI Liangzhou, ZHU Jiming, LIANG Wannian. Application of Modified SEIR Model in Epidemic Prevention and Control: a Real World Study [J]. Chinese General Practice, 2024, 27(01): 118-124. |
[7] | GAO Jinghong, WANG Yanyan, JIANG Shuai, FU Hang, DUAN Yanran, WANG Sufan, WANG Chengzeng. The Applications of Big Data and Artificial Intelligence in the Prevention and Control of COVID-19 from the Perspective of Haddon Model [J]. Chinese General Practice, 2024, 27(01): 111-117. |
[8] | YU Na, BAI Xiaoling, PANG Jin, NIU Yutian, HU Qing, WANG Yuanfang, YANG Rongze. The Experience of Inhaled COVID-19 Vaccination among First-line Medical Staff in Epidemic Prevention Aged≥18 Years in Guiyang City: a Qualitative Study [J]. Chinese General Practice, 2023, 26(36): 4575-4580. |
[9] | XUE Chongxiang, LU Xingyu, LIU Zhening, DONG Huijing, ZHENG Yumin, CUI Huijuan. Dynamic Monitoring of Gene Changes and Its Prognostic Value in Lung Cancer Patients [J]. Chinese General Practice, 2023, 26(36): 4527-4534. |
[10] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[11] | ZHANG Shuai, LI Qin, LI Dongfeng, XIAO Jinping, LI Yunpeng. A Prospective Cohort Study of Solid Fuels Use and Risk of Hypertension in Chinese Older Adults [J]. Chinese General Practice, 2023, 26(32): 4001-4006. |
[12] | CHENG Xiaoran, ZHANG Xiaotian, LI Mingyue, CHENG Haozhe, TANG Haoqing, ZHENG Huixian, ZHANG Baisong, LIU Xiaoyun. Impact of Chronic Diseases Follow-up on Health Behaviors and Blood Pressure/Glucose Control of Patients with Hypertension and Diabetes in the Context of Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(28): 3482-3488. |
[13] | XU Zhe, ZHANG Jinxia, ZHANG Xiuhong, XIE Kaihong. Relationship between Sleep Duration and All-cause Mortality in Middle-aged and Older Adults [J]. Chinese General Practice, 2023, 26(28): 3507-3512. |
[14] | CHEN Lunwen, ZHOU Yang, YAN Guodong, SHEN Yi, SUN Chen, CAI Wanli, CHU Minjie, XIAO Jing. Risk of Malignant Tumor in Patients with Type 2 Diabetes: a Prospective Population-based Study [J]. Chinese General Practice, 2023, 26(26): 3238-3245. |
[15] | WU Jian, YU Chengcheng, YANG Yinmei, XIA Qingyun, LI Quanman, FU Xiaoli. COVID-19 Vaccination Behavior and Its Influencing Factors among the Elderly in Four Regions of China [J]. Chinese General Practice, 2023, 26(22): 2763-2770. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||